{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:23:45Z","timestamp":1767677025622},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.yexcr.2011.02.017","type":"journal-article","created":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T16:01:44Z","timestamp":1302105704000},"page":"1286-1292","source":"Crossref","is-referenced-by-count":11,"title":["Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis"],"prefix":"10.1016","volume":"317","author":[{"given":"Maja","family":"Mircic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.yexcr.2011.02.017_bb0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00832010","article-title":"Therapy of rheumatoid arthritis by blocking Il-6 signal transduction with humanized anti Il-6 receptor antibody","volume":"20","author":"Yoshizaki","year":"1998","journal-title":"Springer Semin. Immunopathol."},{"issue":"7","key":"10.1016\/j.yexcr.2011.02.017_bb0010","first-page":"1426","article-title":"Toxicity, pharmacokinetics and dose finding study of repetitive treatment with the humanized anti-interleukin-6 receptor antibody MRA in rheumatoid arthritis","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.yexcr.2011.02.017_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","volume":"69","author":"Oldfield","year":"2009","journal-title":"Drugs"},{"issue":"9617","key":"10.1016\/j.yexcr.2011.02.017_bb0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.yexcr.2011.02.017_bb0025","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"il-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.yexcr.2011.02.017_bb0030","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, and IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.yexcr.2011.02.017_bb0035","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.yexcr.2011.02.017_bb0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s10165-008-0125-1","article-title":"Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.yexcr.2011.02.017_bb0045","article-title":"Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis(the STREAM study): evidence of safety and efficacy in a 5-year extension study","author":"Nishimoto","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 3","key":"10.1016\/j.yexcr.2011.02.017_bb0050","first-page":"384","article-title":"Tocilizumab inhibits radiographic progression, improves physical function, and gains efficacy over time: LITHE 2year","volume":"69","author":"Fleischmann","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"9617","key":"10.1016\/j.yexcr.2011.02.017_bb0055","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1016\/j.yexcr.2011.02.017_bb0060","first-page":"146","article-title":"From biology to classification and targeted therapy in Juvenile Idiopathic","volume":"69","author":"De Benedetti","year":"2010","journal-title":"Arthritis Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.yexcr.2011.02.017_bb0065","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose escalation trial","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.yexcr.2011.02.017_bb0070","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multi-center, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.yexcr.2011.02.017_bb0075","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482711001078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482711001078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T19:51:20Z","timestamp":1543866680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482711001078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0014482711001078"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2011.02.017","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}